Cormorant Capital

Cormorant Capital

Cormorant Capital

$299,200,000 Venture capital
PE Hub

BridgeBio Pharma racks up $299.2 mln

$50,000,000 Venture capital (Series B)
MedCity News , FinSMEs

Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies

Xconomy

BridgeBio Picks Up Novartis Cancer Drug, Launches New Biotech Startup

Health Science
Xconomy

BridgeBio Bags $135M For “Hub and Spoke” Rare Disease Drug R&D

Health Funding